Skip to main content


Log in

Phase I/II study of docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy in patients with advanced esophageal cancer

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript



This phase I/II study was aimed to determine the recommended dose (RD) of docetaxel, cisplatin, and 5-fluorouracil as combination chemoradiotherapy (DCF-RT) for patients with esophageal cancer and to evaluate the efficacy and safety of this protocol.


Fourteen patients with esophageal cancer enrolled in this dose escalation study to determine the RD for a phase III trial. Efficacy and toxicity in DCF-RT of RD were evaluated in 37 patients with esophageal cancer.


The RD for DCF-RT for esophageal cancer in the present study was 50 mg/m2 docetaxel plus 60 mg/m2 cisplatin on day 1 and day 29 plus 600 mg/m2 5-FU on days 1–4 and days 29–32 and concurrent radiation of 60 Gy/30 fractions/6 weeks. The main toxicities were myelotoxicity and radiation esophagitis. In this phase I/II study, we could have safety and feasibility by RD, because there was low mortality and most toxicities were manageable level. The complete response (CR) rate and response rate were 54.1 and 83.8 %, respectively, in the phase II study. In patients with a classification of clinical T4, the CR rate and response rate were 47.6 and 85.7 %, respectively. The 2-year overall survival rate, 2-year progression-free survival rate, and median survival time (MST) were 52.9, 50.0 %, and 24.7 months, respectively. In patients with clinical T4 classification, the 2-year overall survival rate, 2-year progression-free survival rate, and MST were 43.5, 44.9 %, and 21.6 months respectively.


DCF-RT keeps safety and feasibility by management of myelotoxicity adequately in RD. This protocol might produce a high CR rate and favorable prognosis compared with standard chemoradiotherapy for advanced esophageal cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others


  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90. doi:10.3322/caac.20107

    Article  PubMed  Google Scholar 

  2. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, Gebski V (2011) Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 12(7):681–692. doi:10.1016/s1470-2045(11)70142-5

    Article  PubMed  Google Scholar 

  3. Ajani JA, Ryan B, Rich TA, McMurtrey M, Roth JA, DeCaro L, Levin B, Mountain C (1992) Prolonged chemotherapy for localised squamous carcinoma of the oesophagus. Eur J Cancer 28A(4–5):880–884

    Article  CAS  PubMed  Google Scholar 

  4. Hilgenberg AD, Carey RW, Wilkins EW Jr, Choi NC, Mathisen DJ, Grillo HC (1988) Preoperative chemotherapy, surgical resection, and selective postoperative therapy for squamous cell carcinoma of the esophagus. Ann Thorac Surg 45(4):357–363

    Article  CAS  PubMed  Google Scholar 

  5. Iizuka T, Kakegawa T, Ide H, Ando N, Watanabe H, Tanaka O, Takagi I, Isono K, Ishida K, Arimori M et al (1992) Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol 22(3):172–176

    CAS  PubMed  Google Scholar 

  6. Ohtsu A, Boku N, Muro K, Chin K, Muto M, Yoshida S, Satake M, Ishikura S, Ogino T, Miyata Y, Seki S, Kaneko K, Nakamura A (1999) Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 17(9):2915–2921

    CAS  PubMed  Google Scholar 

  7. Ishida K, Ando N, Yamamoto S, Ide H, Shinoda M (2004) Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). Jpn J Clin Oncol 34(10):615–619. doi:10.1093/jjco/hyh107

    Article  PubMed  Google Scholar 

  8. Muro K, Hamaguchi T, Ohtsu A, Boku N, Chin K, Hyodo I, Fujita H, Takiyama W, Ohtsu T (2004) A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 15(6):955–959

    Article  CAS  PubMed  Google Scholar 

  9. Ajani JA (2002) Docetaxel for gastric and esophageal carcinomas. Oncology (Williston Park, NY) 16(6 Suppl 6):89–96

    Google Scholar 

  10. Miyazaki T, Sohda M, Tanaka N, Suzuki S, Ieta K, Sakai M, Sano A, Yokobori T, Inose T, Nakajima M, Fukuchi M, Ojima H, Kato H, Kuwano H (2013) Phase I dose-escalation study of docetaxel, nedaplatin, and 5-fluorouracil combination chemotherapy in patients with advanced esophageal cancer. Cancer Chemother Pharmacol 71(4):853–857. doi:10.1007/s00280-013-2076-2

    Article  CAS  PubMed  Google Scholar 

  11. Mason KA, Kishi K, Hunter N, Buchmiller L, Akimoto T, Komaki R, Milas L (1999) Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo. Clin Cancer Res 5(12):4191–4198

    CAS  PubMed  Google Scholar 

  12. Hennequin C, Giocanti N, Favaudon V (1996) Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells. Cancer Res 56(8):1842–1850

    CAS  PubMed  Google Scholar 

  13. Higuchi K, Koizumi W, Tanabe S, Sasaki T, Katada C, Ishiyama H, Hayakawa K (2008) A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease and oncology group trial (KDOG 0501). Radiother Oncol 87(3):398–404. doi:10.1016/j.radonc.2008.03.006

    Article  CAS  PubMed  Google Scholar 

  14. Eisterer W, DEV A, Kendler D, Spechtenhauser B, Konigsrainer A, Nehoda H, Virgolini I, Lukas P, Bechter O, Woll E, Ofner D (2011) Triple induction chemotherapy and chemoradiotherapy for locally advanced esophageal cancer. A phase II study. Anticancer res 31(12):4407–4412

    CAS  PubMed  Google Scholar 

  15. Pasini F, de Manzoni G, Zanoni A, Grandinetti A, Capirci C, Pavarana M, Tomezzoli A, Rubello D, Cordiano C (2013) Neoadjuvant therapy with weekly docetaxel and cisplatin, 5-fluorouracil continuous infusion, and concurrent radiotherapy in patients with locally advanced esophageal cancer produced a high percentage of long-lasting pathological complete response: a phase 2 study. Cancer 119(5):939–945. doi:10.1002/cncr.27822

    Article  CAS  PubMed  Google Scholar 

  16. Zanoni A, Verlato G, Giacopuzzi S, Weindelmayer J, Casella F, Pasini F, Zhao E, de Manzoni G (2013) Neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal cancer in a single high-volume center. Ann Surg Oncol 20(6):1993–1999. doi:10.1245/s10434-012-2822-4

    Article  CAS  PubMed  Google Scholar 

  17. Society JE (2009) Japanese classification of esophageal cancer, tenth edition: parts II and III. Esophagus 6(2):71–94. doi:10.1007/s10388-009-0193-0

    Article  Google Scholar 

  18. Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP (2002) INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 20(5):1167–1174

    Article  CAS  PubMed  Google Scholar 

  19. Kato H, Fukuchi M, Manda R, Nakajima M, Miyazaki T, Sohda M, Masuda N, Fukai Y, Tsukada K, Kuwano H (2003) Efficacy and toxicity of nedaplatin and 5-FU with radiation treatment for advanced esophageal carcinomas. Anticancer Res 23(4):3493–3498

    CAS  PubMed  Google Scholar 

  20. Kuwano H, Nishimura Y, Ohtsu A, Kato H, Kitagawa Y, Tamai S, Toh Y, Matsubara H (2008) Guidelines for diagnosis and treatment of carcinoma of the esophagus April 2007 edition: part II edited by the Japan Esophageal Society. Esophagus 5:117–132

    Article  Google Scholar 

  21. Wang S, Tachimori Y, Hokamura N, Igaki H, Nakazato H, Kishino T (2014) Prognostic analysis of salvage esophagectomy after definitive chemoradiotherapy for esophageal squamous cell carcinoma: the importance of lymphadenectomy. J thorac cardiovasc surg 147(6):1805–1811. doi:10.1016/j.jtcvs.2013.12.040

    Article  PubMed  Google Scholar 

  22. Chao YK, Chan SC, Chang HK, Liu YH, Wu YC, Hsieh MJ, Tseng CK, Liu HP (2009) Salvage surgery after failed chemoradiotherapy in squamous cell carcinoma of the esophagus. Eur J Surg Oncol 35(3):289–294. doi:10.1016/j.ejso.2008.02.014

    Article  CAS  PubMed  Google Scholar 

Download references


We thank Ms. Tomoko Yano, Ms. Ayaka Ishikubo, Ms. Ayaka Ishida, Ms. Yuka Matsui, and Ms. Yukie Saito for their excellent assistance. This work was supported in part by the following grants and foundations: Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS); Grant numbers 22591450, 23591857 and 30546726.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Tatsuya Miyazaki.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Miyazaki, T., Sohda, M., Tanaka, N. et al. Phase I/II study of docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy in patients with advanced esophageal cancer. Cancer Chemother Pharmacol 75, 449–455 (2015).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: